ClinicalTrials.gg
RecruitingNCT07250633Updated Jun 5, 2026

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

A Phase 1 interventional study of Vorasidenib 20mg in Severe Hepatic Impairment and Normal Hepatic Function, sponsored by Institut de Recherches Internationales Servier (I.R.I.S.). Recruiting at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Institut de Recherches Internationales Servier (I.R.I.S.) · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of one dose of vorasidenib in participants with severe impaired hepatic function compared to participants with normal hepatic function. The study includes a screening phase, a treatment period, and a follow-up period. During the first part of the treatment period, from Day 1 through Day 4, participants will remain in-house in the clinical research unit. In the second part of the treatment period, from Day 5 through Day 43, participants can go home but may also choose to remain in-house. The entire study, including screening and follow-up, will last up to 77 days. Participants may undergo blood tests, heart tests (electrocardiogram (ECG)), vital sign checks, and physical exams.

02

Conditions studied

  • Severe Hepatic Impairment
  • Normal Hepatic Function
03

In context

Lead sponsor

Institut de Recherches Internationales Servier (I.R.I.S.) is the lead sponsor of 6 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with hepatic impairment:

  • Diagnosis of cirrhosis due to parenchymal liver disease
  • Considered to have a score of 10 to 15, consistent with severe HI, and a documented medical history of liver disease. Participants must be clinically stable (no acute episodes of illness due to deterioration in hepatic function) for at least 1 month prior to screening and are likely to remain stable throughout the study.
  • Grade 0 or Grade 1 hepatic encephalopathy considered stable per Investigator assessment without exacerbation within the 6 months prior to screening.
  • Currently on a stable medication regimen, defined as not starting new drug(s) or significantly changing drug dosage(s) within 14 days preceding Day 1.
  • Non-hepatic abnormal laboratory values must be not as judged by the Investigator (or designee) and the study medical monitor.
  • Anemia secondary to hepatic disease is acceptable if is ≥ 9 g/dL and anemia symptoms are not clinically significant. count must be ≥ 35,000 platelets.
  • corrected for heart rate using Fridericia's formula (QTcF) of ≤ 480 msec.

Matched-control participants:

  • Healthy, with normal hepatic function with a Child-Pugh score below 5.
  • Resting blood pressure of 90 to 140 mmHg (systolic) and 40 to 90 mmHg (diastolic).
  • QTcF of ≤ 450 msec.
  • Participant must match hepatically impaired participants with respect to sex, race, age (±10 years), smoking status (smoke or vape ≤ 10 cigarettes/day), and (±20%).

Exclusion criteria

Exclusion Criteria for all participants:

  • Women of (WOCBP) who are pregnant, lactating, or planning to become pregnant within 90 days after the dose of vorasidenib.
  • The participant is using hormonal
  • Use of any other drug or device within 30 days (or 5 half-lives if known, whichever is longer) before the dose of vorasidenib
  • Consumption of any nutrients known to modulate CYP450 enzymes activity (e.g., grapefruit or grapefruit juice, pomelo juice, star fruit, Seville [blood] orange products) within 14 days before vorasidenib administration.
  • Consumption of alcohol-containing foods or beverages or caffeine- or xanthine-containing foods or beverages (including, but not limited to, teas [including decaffeinated teas], coffees [including decaffeinated coffees], colas [including decaffeinated colas], energy drinks, gum containing caffeine, and chocolate (including foods and beverages containing chocolate) within 48 hours prior to admission
  • Any history (within 5 years prior to screening) or presence of , except for adequately treated basal cell and squamous cell carcinoma of the skin
  • History within the previous 12 months of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 12 oz beer, 5 oz wine, or 1.5 oz spirits)
  • In the opinion of the Investigator, the participant is not suitable for entry into the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Participants with Severe Hepatic Impairment (HI)

    Drug: Vorasidenib 20mg

  • Experimental
    Matched-Participants with Normal Hepatic Function

    Drug: Vorasidenib 20mg

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Through the end of the treatment period (approximately 43 days)

  2. Area under the plasma concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t)

    Time frame: Through the end of the treatment period (approximately 43 days)

  3. AUC from time 0 extrapolated to infinity (AUC0-inf)

    Time frame: Through the end of the treatment period (approximately 43 days)

  4. Time to reach Cmax (Tmax)

    Time frame: Through the end of the treatment period (approximately 43 days)

  5. Apparent terminal elimination half-life (t1/2)

    Time frame: Through the end of the treatment period (approximately 43 days)

  6. Apparent oral clearance (CL/F)

    Time frame: Through the end of the treatment period (approximately 43 days)

  7. Apparent volume of distribution (Vz/F)

    Time frame: Through the end of the treatment period (approximately 43 days)

  8. Apparent terminal elimination rate constant (Kel)

    Time frame: Through the end of the treatment period (approximately 43 days)

Secondary outcomes

  1. Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Through the end of the study (approximately 50 days)

  2. Number of participants experiencing clinically significant changes in laboratory assessments, vital signs, ECG results, or physical examination findings

    Time frame: Through the end of the study (approximately 50 days)

07

Study locations

3 of 3 sites recruiting
  • Arizona Clinical Trials
    Chandler, Arizona 85225, United States
    Recruiting
    • Dr. Anita Kohli · Contact
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
    Recruiting
    • Dr. Thomas Marbury · Contact
  • American Research Corporation
    San Antonio, Texas 78215, United States
    Recruiting
    • Dr. Eric Lawitz · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 26, 2025
StartActual
Apr 23, 2026
Primary completionEst.
Nov 23, 2026
CompletionEst.
Nov 23, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07250633
Lead sponsor
Institut de Recherches Internationales Servier (I.R.I.S.)
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Apr 23, 2026
Primary completion
Nov 23, 2026 (estimated)
Completion
Nov 23, 2026 (estimated)
Last update
Jun 5, 2026

Study contacts

Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Contact
scientificinformation@servier.com
+33 1 55 72 60 00

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorasidenib

Start the discussion